This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: United Kingdom Research and Innovation. Active years: 2019-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2021
Title: Nicolas Phillip James Brindle: Inventor in Angiopoietin-2-Specific TIE2 Receptor Research
Introduction
Nicolas Phillip James Brindle is an inventor based in Leicester, United Kingdom. His patent work includes innovations involving a modified angiopoietin receptor designed to bind preferentially to angiopoietin-2. The available information lists 2 patents associated with him.
Latest Patents
Brindle’s listed patent titles are “Nucleic acid encoding angiopoietin-2 specific Tie2 receptor” and “Angiopoietin-2 specific TIE2 receptor.” Both describe a polypeptide comprising a modified angiopoietin receptor, or a fragment of one, that binds preferentially to angiopoietin-2 rather than angiopoietin-1.
The patent descriptions also cover nucleic acid sequences encoding the polypeptide and potential pharmaceutical uses. These include applications in treating diseases such as cancer and inflammation.
Career Highlights
Brindle’s listed organizational affiliations include United Kingdom Research and Innovation and the Medical Research Council. His patent work reflects research into receptor engineering and potential therapeutic applications.
Collaborations
Julian Edward Sale is listed as a coworker. The available information does not specify the nature or scope of their collaboration.
Conclusion
Nicolas Phillip James Brindle’s listed inventions focus on an angiopoietin-2-specific TIE2 receptor and its potential therapeutic uses, connecting receptor design with research into cancer and inflammation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile